Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.54 |
| ▸ | CCR2 | P41597 | 4/20 | 0.52 |
| ▸ | CCR1 | P32246 | 2/20 | 0.52 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | CCR9 | P51686 | 1/20 | 0.42 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697760 | 0.94 | CCR2 (0.56) | PPARGCCR2CCR1SLC22A12CYP3A4 | |
| SCHEMBL4697780 | 0.89 | PPARG (0.55) | PPARGCCR2CCR1SLC22A12CYP3A4 | |
| SCHEMBL4695656 | 0.83 | PPARG (0.56) | PPARGCCR2CCR1SLC22A12CYP3A4 | |
| SCHEMBL4696073 | 0.82 | PPARG (0.69) | PPARGCYP3A4 | |
| SCHEMBL12584598 | 0.78 | PPARG (0.66) | PPARGSLC22A12CYP3A4 | |
| SCHEMBL12584711 | 0.77 | PPARG (0.65) | PPARGSLC22A12CYP3A4 | |
| SCHEMBL12584896 | 0.77 | CCR2 (0.54) | PPARGCCR2SLC22A12CYP3A4CYP2C9 | |
| SCHEMBL12584774 | 0.76 | PPARG (0.63) | PPARGCCR2SLC22A12CYP3A4CYP2C9 | |
| SCHEMBL12584760 | 0.74 | SLC22A12 (0.66) | PPARGSLC22A12CYP3A4 | |
| SCHEMBL4696569 | 0.73 | PPARG (0.75) | PPARGCCR2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1053227-B1 | PPAR-GAMMA MODULATORS | AMGEN INC (US) | 2008-11-05 | — | — | EP | disclosed |
| US-7439242-B2 | PPARγ modulators | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439242-B2 | PPARγ modulators | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439242-B2 | PPARγ modulators | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-6620827-B2 | Peroxisome proliferator-activated receptors-gamma to control lipid metabolism ane obesity; antidiabetic, -inflammatory and -arthritic agents; non-insulin dependent diabetes; antilipemic and -cholesterol agents | TULARIK INC. | 2003-09-16 | — | — | US | disclosed |
| US-20030088103-A1 | PPARgamma modulators | TULARIK INC. (US) | 2003-05-08 | — | — | US | disclosed |
| US-20010027200-A1 | PPARgamma modulators | TULARIK INC. | 2001-10-04 | — | — | US | disclosed |
| US-6200995-B1 | PYRIDYLOXYBENZENESULFONAMIDE DERIVATIVES; DIABETES, OBESITY | TULARIK INC. | 2001-03-13 | — | — | US | disclosed |
| EP-1053227-A1 | PPAR-GAMMA MODULATORS | TULARIK, INC. (US) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999038845-A1 | PPAR-GAMMA MODULATORS | TULARIK INC. (US) | 1999-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030088103-A1 | PPARgamma modulators | PPARG, PPARA, PPARD | PPARG 1/4885CCR2 1544/4885CCR1 4069/4885 |
| US-20010027200-A1 | PPARgamma modulators | PPARG, PPARA, PPARD | PPARG 1/4885CCR2 1544/4885CCR1 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.